Host: |
HEK293 cells |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Formulation: |
Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Determination Method: |
< 0.1 EU/Mu g of the protein by LAL method. |
Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human ULBP2 Protein at 2 Mu g/mL (100 Mu L/well) can bind NKG2D-raFc with a linear range of 1.95-336.7ng/mL. |
Gene Symbol: |
ULBP2 |
Gene ID: |
80328 |
Uniprot ID: |
ULBP2_HUMAN |
Immunogen: |
Recombinant Human NKG2D ligand 2/ULBP2 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly26-Ser217) of human ULBP2 (Accession #NP_079493.1) fused with an Fc, 6×His tag at the C-terminus. |
Immunogen Sequence: |
GRADPHSLCYDITVIPKFRP GPRWCAVQGQVDEKTFLHYD CGNKTVTPVSPLGKKLNVTT AWKAQNPVLREVVDILTEQL RDIQLENYTPKEPLTLQARM SCEQKAEGHSSGSWQFSFDG QIFLLFDSEKRMWTTVHPGA RKMKEKWENDKVVAMSFHYF SMGDCIGWLEDFLMGMDSTL EPSAGAPLAMSS |
Tissue Specificity | Expressed in various types of cancer cell lines and in the fetus, but not in normal tissues. |
Function | Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity. |
Protein Name | Ul16-Binding Protein 2Alcan-AlphaNkg2d Ligand 2N2dl-2Nkg2dl2Retinoic Acid Early Transcript 1h |
Database Links | Reactome: R-HSA-163125 |
Cellular Localisation | Cell MembraneLipid-AnchorGpi-AnchorEndoplasmic ReticulumSecretedIn Cmv-Infected FibroblastsDetected In The Endoplasmic Reticulum/Cis-Golgi |
Alternative Protein Names | Ul16-Binding Protein 2 proteinAlcan-Alpha proteinNkg2d Ligand 2 proteinN2dl-2 proteinNkg2dl2 proteinRetinoic Acid Early Transcript 1h proteinULBP2 proteinN2DL2 proteinRAET1H proteinUNQ463 proteinPRO791 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance